ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and risk management"

  • Abstract Number: 273 • 2017 ACR/ARHP Annual Meeting

    The Risk Factors of Developing Adult T Cell Leukemia (ATL) in Human T Cell Leukemia Virus Type 1 (HTLV-1) Positive Patients with Rheumatoid Arthritis in Endemic Area, Japan; A Retrospective Cohort Study

    Kunihiko Umekita1, Yayoi Hashiba2, Shunichi Miyauchi1, Kazuyoshi Kubo2, Toshihiko Hidaka2 and Akihiko Okayama1, 1Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, 2Institute of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan

    Background/Purpose: Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia (ATL). ATL is an aggressive T-cell malignancy caused…
  • Abstract Number: 1464 • 2016 ACR/ARHP Annual Meeting

    Utility of Relative Cardiovascular Risk Score Scales and Vascular Age Predictors in Patients with Reumathoid Arthritis UNDER 50 YEARS of Age

    Andrea Zacarias1, Carmen Gomez Vaquero2, Francisco Javier Narváez3, Joan Miquel Nolla4, Miguel Angel González-Gay5, Carlos González-Juanatey6 and Javier Llorca7, 1Hospital Universitari de Bellvitge, Barcelona, Spain, 2Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology, Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, 4Rheumatology, Bellvitge University Hospital, Barcelona, Spain, 5Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, 6Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, 7Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with a greater cardiovascular mortality than the general population of the same age and gender. Cardiovascular events prediction scales,…
  • Abstract Number: 1506 • 2015 ACR/ARHP Annual Meeting

    EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update

    Michael T. Nurmohamed and on behalf of the EULAR task force "EULAR Recommendations for Cardiovascular Risk Management in patients with Rheumatoid Arthritis and other Inflammatory Joint Diseases", Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Patients with rheumatoid arthritis (RA) (and other inflammatory joint diseases (IJD)) have an increased cardiovascular (CV) risk. In 2009 a EULAR taskforce recommended screening,…
  • Abstract Number: 2103 • 2014 ACR/ARHP Annual Meeting

    Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting

    E Alemao1, S Joo2, H Kawabata1, S Banerjee1, M Frits3, C Iannaccone3, N Shadick3 and M Weinblatt3, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Hopewell, NJ, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Guidelines in RA recommend that treatment should be aimed at reaching a target of remission or low disease activity (LDA) as soon as possible,…
  • Abstract Number: 1362 • 2014 ACR/ARHP Annual Meeting

    Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes

    EA Alemao1, S Joo2, S Banerjee1, P Emery3 and M Weinblatt4, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Hopewell, NJ, 3University of Leeds, Leeds, United Kingdom, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Treatment guidelines in RA recommend that therapies aim to reach a target of remission or low disease activity (LDA) and that these targets should…
  • Abstract Number: 1141 • 2014 ACR/ARHP Annual Meeting

    Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression

    E Alemao1, S Joo2, P Allison3, M Al4, M Rutten-van Molken4, S Banerjee1, C Iannaccone5, M Frits5, N Shadick5, M Weinblatt5 and Katherine Liao6, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Hopewell, NJ, 3University of Pennsylvania, Philadelphia, PA, 4Erasmus University, Rotterdam, Netherlands, 5Brigham and Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: We developed and validated a prognostic model to identify subjects with elevated risk of rapid radiographic progression (RRP). The objective of this study was…
  • Abstract Number: 898 • 2014 ACR/ARHP Annual Meeting

    Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting

    J An1, K Reynolds2, E Alemao3, H Kawabata3, D H Solomon4, K P Liao5 and T C Cheetham2, 1Western University of Health Sciences, Pomona, CA, 2Kaiser Permanente Southern California, Pasadena, CA, 3Bristol-Myers Squibb, Princeton, NJ, 4Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Studies have suggested suboptimal care of traditional cardiovascular risk factors (CRF) in patients (pts) with RA as a reason for elevated CV risk compared…
  • Abstract Number: 385 • 2014 ACR/ARHP Annual Meeting

    Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial

    EA Alemao1, S Joo2, S Banerjee1, P Allison3, P Emery4, M Weinblatt5 and Katherine Liao6, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Hopewell, NJ, 3University of Pennsylvania, Philadelphia, PA, 4University of Leeds, Leeds, United Kingdom, 5Brigham and Women's Hospital, Boston, MA, 6Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: We developed and validated a prognostic model for rapid radiographic progression (RRP) using X-ray data to identify RA patients (pts) at risk of structural…
  • Abstract Number: 96 • 2014 ACR/ARHP Annual Meeting

    Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients

    H Cawston1, E Alemao2, F Bourhis1, T Le3, M Al4, M Rutten-van Molken4, Katherine Liao5 and DH Solomon6, 1OptumInsight, Nanterre, France, 2Bristol-Myers Squibb, Princeton, NJ, 3Bristol-Myers Squibb, Hopewell, NJ, 4Erasmus University, Rotterdam, Netherlands, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose : The relative risk of acute myocardial infarction in RA patients (pts) has been shown to range from 1.5 to 2.0, with a 1.4–2.7-fold…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology